Treatment of respiratory diseases
The present invention relates to compositions, methods and kits for the treatment of respiratory disease. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment or prevention of exacerbations of asthma and chronic obstructive pulmonary disease. The present invention provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1, thereby treating or preventing a respiratory disease in a subject. The present invention also provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of ALK5, thereby treating or preventing a respiratory disease in a subject, wherein the inhibitor is administered directly to the airway and/or lungs. The present invention also provides a method of treating or preventing a condition of the airway or lung involving fibrosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1 or an inhibitor of ALK5, thereby treating or preventing a condition of the airway or lung involving fibrosis in a subject.
1. A method of treatment comprising administering to a subject having idiopathic pulmonary fibrosis a therapeutically effective amount of an inhibitor of casein kinase 1, thereby treating idiopathic pulmonary fibrosis in the subject, wherein the inhibitor of casein kinase 1 is
or a pharmaceutically acceptable salt, polymorph or prodrug thereof.
2. The method according to claim 1 , further comprising administering one or more glucocorticoids.
3. The method according to claim 2 , wherein the glucocorticoids are selected from budesonide, ciclesonide and mometasone.
4. The method according to claim 1 , further comprising administering one or more anti-fibrotic compounds.
5. The method according to claim 4 , wherein the anti-fibrotic compounds are selected from nintedanib, tranilast and pirfenidone.